Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice

Anti-Cancer Drugs

Volumn 7, Issue 4, 1996, Pages 437-460

  Bissery, M C ^a   Vrignaud, P ^a   Lavelle, F ^a   Chabot, G G ^b  

^a SANOFI   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Antitumor activity; Camptothecin analog; CPT 11; Irinotecan; Mice; Pharmacokinetics

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; DRUG METABOLITE; IRINOTECAN; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER GRAFT; COLON CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TUMOR LEVEL; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA L 1210; LEUKEMIA P 388; LEWIS CARCINOMA; MALE; MELANOMA B16; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PANCREAS CANCER; PRIORITY JOURNAL; SOLID TUMOR;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LEUKEMIA, EXPERIMENTAL; MALE; MICE; MICE, INBRED STRAINS; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; SENSITIVITY AND SPECIFICITY; TAXOIDS; VINCRISTINE;

EID: 0030014198     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199606000-00010     Document Type: Article

References (48)

1. Wall ME, Wani MC, Cook CE, et al. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1966; 88: 3888-90.
2. Muggia FM, Creaven PJ, Hansen, et al. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880): correlation with preclinical studies. Cancer Chemother Rep 1972; 56: 515-21.
3. Kunimoto T, Nitta K, Tanaka T, et al. Antitumor activity of 7-ethyl-10-14-(1-piperidino)-1-piperidinol-carbonyloxy -camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987; 47: 5944-7.
4. Bissery MC, Mathieu-Boué A, Lavelle F. Experimental antitumor activity of CPT-11 in vitro and in vivo. Ann Oncol 1992; 3: 82, abstr 93.
5. Kawato Y, Furuta T, Aonuma M, et al. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 1991; 28: 192-8.
6. Houghton PJ, Cheshire PJ, Hallman JC, et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidinol-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxy-camptothecin. Cancer Res 1993; 53: 2823-9.
7. Vassal G, Terrier-Lacombe MJ, Bissery MC, et al. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral PNET and neuroblastoma xenografts. Br J Cancer, 1996; in press.
8. Tsuruo T, Matsuzaki T, Matsushita M, et al. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 1988; 21: 71-4.
9. Hsiang YH, Hertzberg R, Hecht S, et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260: 14873-8.
10. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988; 48: 1722-6.
11. Slichenmyer WJ, Rowinsky EK, Donehower RC, et al. The current status of camptothecin analogues as antitumor agents (review). J Natl Cancer Inst 1993; 85: 271-91.
12. Hsiang YH, Liu LF, Wall ME, et al. DNA topoisomerase I mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 1989; 49: 4835-9.
13. Sugimoto Y, Tsukahara S, Oh-Hara T, et al. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 1990; 50: 6925-30.
14. Tsuji T, Kaneda N, Kado K, et al. CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobiodyn 1991; 14: 341-49.
15. Kaneda N, Nagata H, Furuta T, et al. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 1990; 50: 1715-20.
16. Kawato Y, Aonuma M, Hirota Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991; 51: 4187-91.
17. Ohno R, Okada K, Masaoka T, et al. An early phase II study of CPT- 11:a new derivative of camptothecin for the treatment of leukemia and lymphoma. J Clin Oncol 1990; 8: 1907-12.
18. Taguchi T, Wakui A, Hasegawa K. Phase I clinical study of CPT-11. Research Group of CPT-11. Jpn J Cancer Chemother 1990; 17: 115-20.
19. Negoro S, Fukuoka M, Masuda N, et al. Phase I study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer. J Natl Cancer Inst 1991; 83: 1164-8.
20. Catimel G, Chabot GG, Guastalla JP, et al. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol 1995; 6: 133-40.
21. de Forni M, Bugat R, Chabot GG, et al. Phase I and pharmacokinetic study of the camptothecin derivative Irinotecan administered on a weekly schedule in cancer patients. Cancer Res 1994; 54: 4347-54.
22. Fukuoka M, Miitani H, Suzuki A, et al. A Phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer J Clin Oncol 1992; 10: 16-20.
23. Abigerges D, Chabot GG, Armand JP, et al. Phase I and pharmacologic studies of the camptothecin analogue irinotecan (CPT-11) administered every three weeks in cancer patient. J Clin Oncol 1995; 13: 210-21
24. Ohe Y, Sasaki Y, Shinkai T, et al. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 1992; 84: 972-4.
25. Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative in metastatic colorectal cancer. J Clin Oncol 1993; 11: 909-13.
26. Rothenberg ML, Kuhn JG, Burris III HA, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993; 11: 2194-204.
27. Rowinsky EK, Grochow L, Ettinger DS, et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 1994; 54: 427-36.
28. Chabot GG, Abigerges D, Catimel G, et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 1995; 6: 141-51.
29. Lorusso P, Wozniak AJ, Polin L, et al. Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice. Cancer Res 1990; 50: 4900-5.
30. Corbett TH, Griswold DP Jr, Roberts BJ, et al. Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 1977; 40: 2660-80.
31. Corbett TH, Roberts BJ, Leopold WR, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57B1/6 mice. Cancer Res 1984; 44: 717-26.
32. Corbett TH, Griswold DP Jr, Roberts BJ, et al. Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat Rep 1978; 62: 1471-99.
33. Gioanni J, Courdi A, Lalanne CM, et al. Establishment, characterization, chemosensitivity and radiosensitivity of two different cell lines derived from a human breast cancer biopsy. Cancer Res 1985; 45: 1246-58.
34. Glasgow LA, Crane JL Jr, Kern ER. Antitumor activity of interferon against murine osteogenic sarcoma cells in vitro. J Natl Cancer Inst 1978; 60: 659-63.
35. Mayo JG. Biologic characterization of the subcutaneously implanted Lewis lung tumor. Cancer Chemother Rep 1972; 3: 325-30.
36. Geran RI, Greenberg NH, Macdonald MM, et al. Protocols for screening chemical agents and natural products against animal tumors and other biological systems (third edition). Cancer Chemother Rep 1972; 3: 1-103.
37. Schabel FM Jr, Skipper HE, Trader MW, et al. Establishment of cross-resistance profiles for new agents. Cancer Treat Rep 1983; 67: 905-22.
38. Riou JF, Petitgenet O, Aynié I, Lavelle F. Establishment and characterization of docetaxel (Taxotere®) resistant human breast carcinoma (Calc18/TXT) and murine leukemic (P388/TXT) cell lines (Abstract). Proc Am Ass Cancer Res 1994, 35: 339.
39. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977; 197: 461-3.
40. Salmon SE, Hamburger AW, Soehnlen B, et al. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. New Eng J Med 1978; 298: 1321-7.
41. Alberts DS, Salmon SE, Chen HSG, et al. Pharmacologic studies of anticancer drugs with the human tumor stem cell assay. Cancer Chemother Pharmacol 1981; 6: 253-64.
42. Corbett TH, Wozniak A, Gerpheide S, Hanka L. A selective two-tumor soft agar assay for drug discovery In: White E, ed. In vitro and in vivo models for detection of new antitumor drugs (14th International Congress of Chemotherapy). Tokyo: University of Tokyo Press 1985: 5-14.
43. Corhett TH, Roberts BJ, Trader MW, et al. Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents. Cancer Treat Rep 1982; 66: 1187-200.
44. Corbett TH, Leopold WR, Dykes DJ, et al. Toxicity and anticancer activity of a new triazine antifolate (NSC 127755). Cancer Res 1982; 42: 1701-15.
45. Slichenmyer WJ, Rowinski EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993; 85: 271-91.
46. Barilero I, Gandia D, Armand JP, et al. Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography - application to plasma pharmacokinetic studies in cancer patients. J Chromatogr (Biomed Appl) 1992; 575: 275-80.
47. Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn. New-York: Marcel Dekker 1992.
48. Shimada Y, Rothenberg M, Hilsenbeck SG, Burris III HA, Degen D, Von Hoff DD. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anti-Cancer Drugs 1994; 5: 202-6.